The portfolio began investing on 10 November and holds twelve companies whose reported growth is accelerating or compounding. Each purchase this week followed a dated company report.
On 10 November it bought Microsoft, on results of 28 October showing Azure cloud revenue up 48% in constant currency; Eli Lilly, on results of 29 October in which volume rose 53% while prices fell 15%; Kiniksa Pharmaceuticals, whose 27 October report showed ARCALYST revenue up 58% to $286.0 million; and Unity Software and Appian, both on results of 5 November. Unity's Grow advertising revenue rose 90% to $431.5 million, with its first quarterly net profit since listing, and Appian's revenue rose 25% to $234.6 million.
On 11 November it bought Palomar Holdings, which on 4 November raised its 2026 adjusted net income guidance for the fourth time, to $280–285 million, and Zeta Global, whose 9 November results showed revenue up 46% to $492.7 million.
On 12 November it bought Chime Financial (results of 4 November: revenue up 32% to $718.0 million), QuinStreet (4 November: revenue up 46% to $416.7 million and a raised full-year outlook), Eton Pharmaceuticals (5 November: revenue up 158% to $57.9 million) and Xeris Biopharma (5 November: Recorlev sales up 93% to $71.5 million).
On 13 November it bought IMAX, whose 5 November results showed revenue up 64% to $174.6 million, and added to Eli Lilly after China approved its Foundayo weight-loss pill, reported on 12 November.
Most of these shares had already risen on their reports, so the holdings rest on growth continuing, not on a low price. Business facts, not price moves, would change the view: Azure growth below 47% in Microsoft's December quarter; Lilly's 2027 revenue guidance implying growth under about 15%; Unity's fourth-quarter Grow revenue below the guided $515 million; QuinStreet's December-quarter revenue below $360 million; Chime's fourth-quarter revenue below $757 million; Palomar's 2027 guidance implying profit growth below about 10%. For the other holdings the tests are Kiniksa's first 2027 sales outlook, Zeta's organic growth, Appian's cloud revenue, IMAX's 2027 box-office guidance, and whether the lead drugs at Eton and Xeris keep growing each quarter.
Two Microsoft events this week, a rival's spreadsheet launch on 10 November and a Microsoft 365 outage on 12–13 November, do not bear on the Azure test.
More from the portfolio
The portfolio page lists every holding with the case it was bought on and every change with the dated fact behind it. Follow @frontierpicks on X or the RSS feed.